Sequenom Announces Participation at the 22nd Annual Oppenheimer and Company Healthcare Conference
Dec 5, 2011
SAN DIEGO, Dec. 5, 2011 /PRNewswire/ -- Sequenom, Inc. (NASDAQ: SQNM), a life sciences company providing innovative genetic analysis solutions, today announced the Company's participation at the 22nd Annual Oppenheimer Healthcare Conference at the Waldorf Astoria Hotel in New York City December 13-14, 2011.
Ronald M. Lindsay, Ph.D., Director and EVP of Research will present on Wednesday, December 14, 2011 beginning at 1:35 p.m. ET, to provide an overview of and update on the Company. The presentation is expected to last approximately 30 minutes and will be web cast live through the "Investors" section of the Sequenom website at www.sequenom.com. An audio replay will be available for 30 days following the initial presentation web cast.
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular diagnostics markets. The company was founded in 1994 and is headquartered in San Diego, California. Sequenom maintains a Web site at http://www.sequenom.com to which Sequenom regularly posts copies of its press releases as well as additional information about Sequenom. Interested persons can subscribe on the Sequenom Web site to email alerts or RSS feeds that are sent automatically when Sequenom issues press releases, files its reports with the Securities and Exchange Commission or posts certain other information to the Web site.
SOURCE Sequenom, Inc.
For further information: CONTACT: Marcy Graham, Senior Director, Investor Relations & Corp Comm, Sequenom, Inc., +1-858-202-9028, email@example.com; or Jakob Jakobsen, Media, Chandler Chicco Agency, +1-310-309-1003, firstname.lastname@example.org